Importance of antiresorptive therapies for patients with bone metastases from solid tumors

References

• ColemanREMetastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treat Rev200127316517611417967
   PubMed Web of Science ®Google Scholar
• SaadFNew research findings on zoledronic acid: survival, pain, and anti-tumor effectsCancer Treat Rev200834218319218061356
   PubMed Web of Science ®Google Scholar
• WeinfurtKPLiYCastelLDThe significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancerAnn Oncol200516457958415734776
   PubMed Web of Science ®Google Scholar
• FizaziKCarducciMSmithMDenosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyLancet2011377976881382221353695
   PubMed Web of Science ®Google Scholar
• HenryDHCostaLGoldwasserFRandomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myelomaJ Clin Oncol20112991125113221343556
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDKaminskiMLong-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trialCancer20039881735174414534891
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDTchekmedyianNSLong-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trialCancer2004100122613262115197804
   PubMed Web of Science ®Google Scholar
• SaadFGleasonDMMurrayRLong-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancerJ Natl Cancer Inst2004961187988215173273
   PubMed Web of Science ®Google Scholar
• StopeckATLiptonABodyJJDenosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind studyJ Clin Oncol201028355132513921060033
   PubMed Web of Science ®Google Scholar
• LiptonATheriaultRLHortobagyiGNPamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trialsCancer20008851082109010699899
   PubMed Web of Science ®Google Scholar
• Zometa^® [prescribing information]East Hanover, NJNovartis Pharmaceuticals Corporation2011
   Google Scholar
• Xgeva^® [prescribing information]Thousand Oaks, CAAmgen Inc2010
   Google Scholar
• MundyGRMetastasis to bone: causes, consequences and therapeutic opportunitiesNat Rev Cancer20022858459312154351
   PubMed Web of Science ®Google Scholar
• SaadFGleasonDMMurrayRA randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaJ Natl Cancer Inst200294191458146812359855
   PubMed Web of Science ®Google Scholar
• KohnoNAogiKMinamiHZoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trialJ Clin Oncol200523153314332115738536
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJLichinitserMRIntravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesAnn Oncol20031491399140512954579
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJLichinitzerMOral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled Phase III studiesBr J Cancer20049061133113715026791
   PubMed Web of Science ®Google Scholar
• KristensenBEjlertsenBGroenvoldMHeinSLoftHMouridsenHTOral clodronate in breast cancer patients with bone metastases: a randomized studyJ Intern Med19992461677410447227
   PubMed Web of Science ®Google Scholar
• PatersonAHPowlesTJKanisJAMcCloskeyEHansonJAshleySDouble-blind controlled trial of oral clodronate in patients with bone metastases from breast cancerJ Clin Oncol199311159658418243
   PubMed Web of Science ®Google Scholar
• Tubiana-HulinMBeuzebocPMauriacLDouble-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastasesBull Cancer2001887701707 French11495824
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDKaminskiMZoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trialCancer J20017537738711693896
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDTchekmedyianSZoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial – the Zoledronic Acid Lung Cancer and Other Solid Tumors Study GroupJ Clin Oncol200321163150315712915606
   PubMed Web of Science ®Google Scholar
• MorganGJDaviesFGregoryWZoledronic acid prolongs time to first skeletal-related event, progression-free survival, and overall survival versus clodronate in newly diagnosed multiple myeloma: MRC Myeloma IX trial resultsAbstract 0562 presented at the 15th Congress of the European Hematology AssociationJune 10–13, 2010Barcelona, Spain
   Google Scholar
• MorganGJDaviesFEGregoryWMFirst-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialLancet201037697571989199921131037
   PubMed Web of Science ®Google Scholar
• PavlakisNSchmidtRStocklerMBisphosphonates for breast cancerCochrane Database Syst Rev20053CD00347416034900
   PubMedGoogle Scholar
• Aredia^® [prescribing information]East Hanover, NJNovartis Pharmaceuticals Corporation2011
   Google Scholar
• RogersMJGordonSBenfordHLCellular and molecular mechanisms of action of bisphosphonatesCancer200088Suppl 122961297810898340
   PubMedGoogle Scholar
• DunfordJEThompsonKCoxonFPStructure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonatesJ Pharmacol Exp Ther2001296223524211160603
   PubMed Web of Science ®Google Scholar
• GreenJRMullerKJaeggiKAPreclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compoundJ Bone Miner Res1994957457518053405
   PubMed Web of Science ®Google Scholar
• HadjiPClinical considerations for the use of antiresorptive agents in the treatment of metastatic bone diseaseCrit Rev Oncol Hematol201180230131321511491
   PubMed Web of Science ®Google Scholar
• GreenJRGuentherAThe backbone of progress – preclinical studies and innovations with zoledronic acidCrit Rev Oncol Hematol201177 Suppl 1S3S1221353178
   PubMed Web of Science ®Google Scholar
• Neville-WebbeHLGnantMColemanREPotential anticancer properties of bisphosphonatesSemin Oncol201037 Suppl 1S53S6520682373
   PubMed Web of Science ®Google Scholar
• WinterMCHolenIColemanREExploring the anti-tumour activity of bisphosphonates in early breast cancerCancer Treat Rev200834545347518423992
   PubMed Web of Science ®Google Scholar
• ColemanREWinterMCCameronDThe effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerBr J Cancer201010271099110520234364
   PubMed Web of Science ®Google Scholar
• PowlesTPatersonAMcCloskeyEReduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]Breast Cancer Res200682R1316542503
   PubMed Web of Science ®Google Scholar
• DielIJSolomayerEFCostaSDReduction in new metastases in breast cancer with adjuvant clodronate treatmentN Engl J Med199833963573639691101
   PubMed Web of Science ®Google Scholar
• DielIJJaschkeASolomayerEFAdjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-upAnn Oncol200819122007201118664560
   PubMed Web of Science ®Google Scholar
• SaartoTBlomqvistCVirkkunenPElomaaIAdjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trialJ Clin Oncol2001191101711134190
   PubMed Web of Science ®Google Scholar
• SaartoTVehmanenLVirkkunenPBlomqvistCTen-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patientsActa Oncol200443765065615545185
   PubMed Web of Science ®Google Scholar
• PatersonAHGAndersonSJLemberskyBCNSABP protocol B-34: a clinical trial comparing adjuvant clodronate vs placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy – final analysisAbstract S2–3 presented at the CTRC-AACR San Antonio Breast Cancer SymposiumDecember 6–10, 2011San Antonio, TX
   Google Scholar
• MobusVDielIJHarbeckNGAIN (German Adjuvant Intergroup Node Positive) study: a phase-III multicenter trial to compare dose dense, dose intense ETC (iddETC) vs EC-TX and ibandronate vs observation in patients with node-positive primary breast cancer – 1st interim EFFICACY analysisAbstract S2–4 presented at the CTRC-AACR San Antonio Breast Cancer SymposiumDecember 6–10, 2011San Antonio, TX
   Google Scholar
• LinAYParkJWScottJZoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrowJ Clin Oncol200826Suppl 1520sAbstract559
   Web of Science ®Google Scholar
• SolomayerEFGebauerGHirnlePInfluence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patientsPoster 2048 presented at the 31st Annual San Antonio Breast Cancer SymposiumDecember 10–14, 2008San Antonio, TX
   Google Scholar
• AftRNaughtonMTrinkausKEffect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialLancet Oncol201011542142820362507
   PubMed Web of Science ®Google Scholar
• RackBJuckstockJGenssEMEffect of zoledronate on persisting isolated tumour cells in patients with early breast cancerAnticancer Res20103051807181320592383
   PubMed Web of Science ®Google Scholar
• EidtmannHde BoerRBundredNEfficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST studyAnn Oncol2010212188219420444845
   PubMed Web of Science ®Google Scholar
• de BoerRBundredNEidtmannHThe effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-upPoster P5-11-01 presented at the 33rd Annual San Antonio Breast Cancer SymposiumDecember 8–12, 2010San Antonio, TX
   Google Scholar
• GnantMMlineritschBSchippingerWEndocrine therapy plus zoledronic acid in premenopausal breast cancerN Engl J Med2009360767969119213681
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBLuschin-EbengreuthGLong-term follow-up in ABCSG-12: Significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with hormone-receptor-positive early breast cancerAbstract S1–2 presented at the CTRC-AACR San Antonio Breast Cancer SymposiumDecember 6–10, 2011San Antonio, TX
   Google Scholar
• ColemanREMarshallHCameronDBreast-cancer adjuvant therapy with zoledronic acidN Engl J Med2011365151396140521995387
   PubMed Web of Science ®Google Scholar
• MystakidouKKatsoudaEParpaEKelekisAGalanosAVlahosLRandomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baselineMed Oncol200522219520115965284
   PubMed Web of Science ®Google Scholar
• ZaghloulMSBoutrusREl-HossienyHKaderYAEl-AttarINazmyMA prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancerInt J Clin Oncol201015438238920354750
   PubMed Web of Science ®Google Scholar
• ZarogoulidisKBoutsikouEZarogoulidisPThe impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasisInt J Cancer200912571705170919521984
   PubMed Web of Science ®Google Scholar
• AvilesANamboMJNeriNCastanedaCCletoSHuerta-GuzmanJAntitumor effect of zoledronic acid in previously untreated patients with multiple myelomaMed Oncol200724222723017848748
   PubMed Web of Science ®Google Scholar
• HamiltonEClayTMBlackwellKLNew perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune responseCancer Invest201129853354121843051
   PubMed Web of Science ®Google Scholar
• BoyleWJSimonetWSLaceyDLOsteoclast differentiation and activationNature2003423693733734212748652
   PubMed Web of Science ®Google Scholar
• RoodmanGDMechanisms of bone metastasisN Engl J Med2004350161655166415084698
   PubMed Web of Science ®Google Scholar
• BachmannMFKopfMThe role of B cells in acute and chronic infectionsCurr Opin Immunol199911333233910375561
   PubMed Web of Science ®Google Scholar
• KimHHShinHSKwakHJRANKL regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathwayFASEB J200317142163216514500543
   PubMed Web of Science ®Google Scholar
• TheillLEBoyleWJPenningerJMRANK-L and RANK: T cells, bone loss, and mammalian evolutionAnnu Rev Immunol20022079582311861618
   PubMed Web of Science ®Google Scholar
• KartsogiannisVZhouHHorwoodNJLocalization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissuesBone199925552553410574572
   PubMed Web of Science ®Google Scholar
• BoneHGBologneseMAYuenCKEffects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone massJ Clin Endocrinol Metab201196497298021289258
   PubMed Web of Science ®Google Scholar
• MillerPDBologneseMALewieckiEMEffect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trialBone200843222222918539106
   PubMed Web of Science ®Google Scholar
• StopeckALiptonAMartinMDenosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2-year open-label extension treatment phase of a pivotal phase 3 studyAbstract P3-16-07 presented at the San Antonio Breast Cancer SymposiumDecember 6–10, 2011San Antonio, TX
   Google Scholar
• LiptonASienaSRaderMComparison of denosumab versus zoledronic acid for treatment of bone metastases in advanced cancer patients: an integrated analysis of 3 pivotal trialsPoster 1249P presented at the 35th ESMO CongressOctober 8–12, 2010Milan, Italy
   Google Scholar
• SmithMRSaadFColemanRDenosumab and bone- metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialLancet20123799810394622093187
   PubMed Web of Science ®Google Scholar
• US National Institutes of HealthStudy to determine treatment effects of denosumab in patients with breast cancer receiving aromatase inhibitor therapy Available from: http://www.clinicaltrials.gov/ct2/show/NCT00556374?term=NCT00556374&rank=1Accessed May 8, 2012
   Google Scholar
• US National Institutes of HealthClinicalTrials.govStudy of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D-CARE) Available from: http://www.clinicaltrials.gov/ct2/show/NCT01077154?term=NCT01077154&rank=1Accessed May 8, 2012
   Google Scholar
• AaproMAbrahamssonPABodyJJGuidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panelAnn Oncol200819342043217906299
   PubMed Web of Science ®Google Scholar
• TanvetyanonTStiffPJManagement of the adverse effects associated with intravenous bisphosphonatesAnn Oncol200617689790716547070
   PubMed Web of Science ®Google Scholar
• MaxwellCSwiftRGoodeMDoaneLRogersMAdvances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acidClin J Oncol Nurs20037440340812929273
   PubMedGoogle Scholar
• SaadFBrownJEVan PoznakCIncidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastasesAnn Oncol20122351341134721986094
   PubMed Web of Science ®Google Scholar
• ColemanRBundredNde BoerRImpact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FASTAbstract 4082 presented at the 32nd Annual San Antonio Breast Cancer SymposiumDecember 9–13, 2009San Antonio, TX
   Google Scholar
• EllisGKBoneHGChlebowskiRRandomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancerJ Clin Oncol200826304875488218725648
   PubMed Web of Science ®Google Scholar
• RipamontiCIManiezzoMCampaTDecreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of MilanAnn Oncol200920113714518647964
   PubMed Web of Science ®Google Scholar
• BadrosATerposEKatodritouENatural history of osteonecrosis of the jaw in patients with multiple myelomaJ Clin Oncol200826365904590919018084
   PubMed Web of Science ®Google Scholar
• RuggieroSLDodsonTBAssaelLALandesbergRMarxREMehrotraBAmerican Association of Oral and Maxillofacial SurgeonsPosition paper on bisphosphonate-related osteonecrosis of the jaw – 2009 updateAust Endod J20093511913019961450
   PubMed Web of Science ®Google Scholar
• Launay-VacherVEpidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study groupSemin Nephrol201030654855621146120
   PubMed Web of Science ®Google Scholar
• Launay-VacherVIzzedineHReyJBIncidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patientsMed Sci Monit2004105CR209CR21215114271
   PubMed Web of Science ®Google Scholar
• Launay-VacherVSpanoJPJanusNRenal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA studyCrit Rev Oncol Hematol200970212413318990585
   PubMed Web of Science ®Google Scholar
• StevensLALiSWangCPrevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP)Am J Kidney Dis2010553 Suppl 2S23S3320172445
   PubMed Web of Science ®Google Scholar
• Launay-VacherVOudardSJanusNPrevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the Renal Insufficiency and Anticancer Medications (IRMA) studyCancer200711061376138417634949
   PubMed Web of Science ®Google Scholar
• National Kidney FoundationK/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratificationAm J Kidney Dis200239Suppl 1S1S26611904577
   PubMed Web of Science ®Google Scholar
• LichtmanSMVillaniGChemotherapy in the elderly: pharmacologic considerationsCancer Control20007654855611088063
   PubMedGoogle Scholar
• SahniVChoudhuryDAhmedZChemotherapy-associated renal dysfunctionNat Rev Nephrol20095845046219564889
   PubMed Web of Science ®Google Scholar
• Launay-VacherVJanusNKarieSDerayGLetter. Systemic anticancer therapy in gynecological cancer patients with renal dysfunctionInt J Gynecol Cancer20071761340134117997797
   PubMed Web of Science ®Google Scholar
• Bondronat [summary of product characteristics]Roche Diagnostics GmbH and Roche Products Limited Available from: http://www.medicines.org.uk/EMC/printfriendlydocument.aspx?documentid=8600&compPublished. Revised August 9, 2011Accessed May 8, 2012
   Google Scholar
• Bondronat [Professional Information Swiss Drug Compendium]Roche Pharma (Schweiz) AG Available from: http://www.kompendium.ch/MonographieTxt.aspx?lang=fr&MonType=fi. Published April, 2009Accessed May 8, 2012
   Google Scholar
• DranitsarisGHatzimichaelEInterpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patientsSupport Care Cancer20122071353136022539050
   PubMed Web of Science ®Google Scholar
• SnedecorSJCarterJAKauraSBottemanMFCost-effectiveness of zoledronic acid versus denosumab in prevention of skeletal-related events in castration-resistant prostate cancer metastatic to the boneAbstract 4581 presented at the 2011 ASCO Annual MeetingJune 3–7, 2011Chicago, IL
   Google Scholar
• SnedecorSJCarterJAKauraSBottemanMFCost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancerClin Ther20123461334134922578308
   PubMed Web of Science ®Google Scholar
• StopeckARaderMHenryDCost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United StatesJ Med Econ201215471272322409231
   PubMedGoogle Scholar